BCKDK and breast cancer: Here we show that inhibition of BCKDK using either siRNA or the chemical inhibitors 3,6-dichlorobenzothiophene-2-carboxylic acid (BT2/DCBC) or (S)-2-chloro-4-methylvaleric acid (CMVA) increases the sensitivity of ovarian and breast cancer cells to paclitaxel.